Biotech, Cannabis, Food & Drug, & Pharma Law Updates

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotech, Cannabis, Food & Drug, & Pharma Administration News

Title
Publication Date Organization
Nov
28
2023
New Year, New Laws: California Employment Law Updates for 2024 Mintz
Nov
28
2023
Senators Propose Bill to Eliminate Self-Affirmed GRAS Keller and Heckman LLP
Nov
28
2023
Third-Party Drug-Testers—Not Just Employers—Owe no Duty to Employees Hunton Andrews Kurth
Nov
27
2023
Artificial Sweeter Decision Sours Halal Authority: Halal Certification Authority Pty Limited V Flujo Sanguineo Holdings Pty Limited [2023] FCAFC 175 K&L Gates
Nov
27
2023
Ohio Legalizes Recreational Use of Marijuana Foley & Lardner LLP
Nov
27
2023
California Attorney General Issues Stark Warning to Businesses Regarding Enforcement of PFAS in Food Packaging and Cookware Laws Hunton Andrews Kurth
Nov
27
2023
Dude, Where’s My Liquidation? Bradley Arant Boult Cummings LLP
Nov
27
2023
Unpacking Packaging, Labeling, Preparation, and Destruction of Cannabis Products under SB 846 Norris McLaughlin P.A.
Nov
27
2023
O-high-o: Ohio Voters vote to Legalize Recreational Cannabis Norris McLaughlin P.A.
Nov
27
2023
Back Pain, Legal Strains, and CBD Gains: Pennsylvania Court’s High Stakes Ruling on CBD Compensation Norris McLaughlin P.A.
Nov
27
2023
FDA Releases Infant Formula Risk Management Plan Fact Sheet Keller and Heckman LLP
Nov
23
2023
EC Asks SCCS to Assess Safety of Hydroxyapatite (Nano) in View of New Information Bergeson & Campbell, P.C.
Nov
22
2023
Global Regulatory Update for November 2023 Bergeson & Campbell, P.C.
Nov
22
2023
FDA Delays Enforcement of MOCRA Deadlines for Facility Registration and Product Listing to July 1, 2024 Squire Patton Boggs (US) LLP
Nov
22
2023
Elevated Lead Levels Found in Children’s Fruit Pouches: Anatomy of a Recall Womble Bond Dickinson (US) LLP
Nov
22
2023
FDA Published Updated Leafy Green STEC Action Plan Keller and Heckman LLP
Nov
22
2023
Canadian Court Invalidates Plastics ‘Toxic’ Designation Keller and Heckman LLP
Nov
22
2023
FTC Warns Influencers and Trade Associations to Be Much More Specific About Ties Hunton Andrews Kurth
Nov
21
2023
Petition Requests that FDA Amend Flavoring Regulation Keller and Heckman LLP
Nov
21
2023
Voluntary Self-Disclosure of FCPA Violations Following Acquisition Avoids Corruption Charges Sheppard, Mullin, Richter & Hampton LLP
Nov
20
2023
FDA Announces Updates to Dietary Supplement Program Greenberg Traurig, LLP
Nov
20
2023
Sharing Scientific Information with HCPs on Unapproved Uses of Medical Products: Dos and Don’ts Under FDA’s New Draft Guidance Epstein Becker & Green, P.C.
Nov
20
2023
The LDT Debate: Unpacking Public Responses to FDA’s Proposed Rule Mintz
Nov
20
2023
Big Brother Cancels Trip, Court Says Not So Fast My Friend Bradley Arant Boult Cummings LLP
Nov
20
2023
Imported Cantaloupe Recalled in U.S. and Canada Keller and Heckman LLP
Nov
17
2023
HHS Issues Provider Information Blocking Disincentives Proposed Rule McDermott Will & Emery
Nov
17
2023
Indecent Disclosure: FTC Slams Advertisers and Influencers for Failure to Divulge Material Connections Mintz
Nov
17
2023
Revisiting FDA’s Original Guidance on Orange Book Listability in Light of Heightened FTC Scrutiny Foley & Lardner LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins